Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas

S. K.A. Divakar, M. V. Ramana Reddy, S. C. Cosenza, S. J. Baker, D. Perumal, A. C. Antonelli, J. Brody, B. Akula, S. Parekh, E. Premkumar Reddy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This study describes the characterization of a novel kinase inhibitor, ON123300, which inhibits CDK4/6 (cyclin-dependent kinases 4 and 6) and phosphatidylinositol 3 kinase-δ (PI3K-δ) and exhibits potent activity against mantle cell lymphomas (MCLs) both in vitro and in vivo. We examined the effects of PD0332991 and ON123300 on cell cycle progression, modulation of the retinoblastoma (Rb) and PI3K/AKT pathways, and the induction of apoptosis in MCL cell lines and patient-derived samples. When Granta 519 and Z138C cells were incubated with PD0332991 and ON123300, both compounds were equally efficient in their ability to inhibit the phosphorylation of Rb family proteins. However, only ON123300 inhibited the phosphorylation of proteins associated with the PI3K/AKT pathway. Cells treated with PD0332991 rapidly accumulated in the G0/G1 phase of cell cycle as a function of increasing concentration. Although ON123300-treated cells arrested similarly at lower concentrations, higher concentrations resulted in the induction of apoptosis, which was not observed in PD0332991-treated samples. Mouse xenograft assays also showed a strong inhibition of MCL tumor growth in ON123300-treated animals. Finally, treatment of ibrutinib-sensitive and-resistant patient-derived MCLs with ON123300 also triggered apoptosis and inhibition of the Rb and PI3K/AKT pathways, suggesting that this compound might be an effective agent in MCL, including ibrutinib-resistant forms of the disease.

Original languageEnglish (US)
Pages (from-to)86-93
Number of pages8
JournalLeukemia
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Retinoblastoma
Phosphatidylinositol 3-Kinases
Apoptosis
Cell Cycle
Cyclin-Dependent Kinase 6
Phosphorylation
Cyclin-Dependent Kinase 4
Phosphatidylinositol 3-Kinase
Retinoblastoma Protein
Cell Cycle Resting Phase
Aptitude
G1 Phase
Synthetic Lethal Mutations
Inhibition (Psychology)
ON123300
Heterografts
Phosphotransferases
Cell Line
palbociclib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Divakar, S. K. A., Ramana Reddy, M. V., Cosenza, S. C., Baker, S. J., Perumal, D., Antonelli, A. C., ... Premkumar Reddy, E. (2016). Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia, 30(1), 86-93. https://doi.org/10.1038/leu.2015.185

Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. / Divakar, S. K.A.; Ramana Reddy, M. V.; Cosenza, S. C.; Baker, S. J.; Perumal, D.; Antonelli, A. C.; Brody, J.; Akula, B.; Parekh, S.; Premkumar Reddy, E.

In: Leukemia, Vol. 30, No. 1, 01.01.2016, p. 86-93.

Research output: Contribution to journalArticle

Divakar, SKA, Ramana Reddy, MV, Cosenza, SC, Baker, SJ, Perumal, D, Antonelli, AC, Brody, J, Akula, B, Parekh, S & Premkumar Reddy, E 2016, 'Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas', Leukemia, vol. 30, no. 1, pp. 86-93. https://doi.org/10.1038/leu.2015.185
Divakar SKA, Ramana Reddy MV, Cosenza SC, Baker SJ, Perumal D, Antonelli AC et al. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia. 2016 Jan 1;30(1):86-93. https://doi.org/10.1038/leu.2015.185
Divakar, S. K.A. ; Ramana Reddy, M. V. ; Cosenza, S. C. ; Baker, S. J. ; Perumal, D. ; Antonelli, A. C. ; Brody, J. ; Akula, B. ; Parekh, S. ; Premkumar Reddy, E. / Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. In: Leukemia. 2016 ; Vol. 30, No. 1. pp. 86-93.
@article{ac647bfa475f48019b1b790022e6386e,
title = "Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas",
abstract = "This study describes the characterization of a novel kinase inhibitor, ON123300, which inhibits CDK4/6 (cyclin-dependent kinases 4 and 6) and phosphatidylinositol 3 kinase-δ (PI3K-δ) and exhibits potent activity against mantle cell lymphomas (MCLs) both in vitro and in vivo. We examined the effects of PD0332991 and ON123300 on cell cycle progression, modulation of the retinoblastoma (Rb) and PI3K/AKT pathways, and the induction of apoptosis in MCL cell lines and patient-derived samples. When Granta 519 and Z138C cells were incubated with PD0332991 and ON123300, both compounds were equally efficient in their ability to inhibit the phosphorylation of Rb family proteins. However, only ON123300 inhibited the phosphorylation of proteins associated with the PI3K/AKT pathway. Cells treated with PD0332991 rapidly accumulated in the G0/G1 phase of cell cycle as a function of increasing concentration. Although ON123300-treated cells arrested similarly at lower concentrations, higher concentrations resulted in the induction of apoptosis, which was not observed in PD0332991-treated samples. Mouse xenograft assays also showed a strong inhibition of MCL tumor growth in ON123300-treated animals. Finally, treatment of ibrutinib-sensitive and-resistant patient-derived MCLs with ON123300 also triggered apoptosis and inhibition of the Rb and PI3K/AKT pathways, suggesting that this compound might be an effective agent in MCL, including ibrutinib-resistant forms of the disease.",
author = "Divakar, {S. K.A.} and {Ramana Reddy}, {M. V.} and Cosenza, {S. C.} and Baker, {S. J.} and D. Perumal and Antonelli, {A. C.} and J. Brody and B. Akula and S. Parekh and {Premkumar Reddy}, E.",
year = "2016",
month = "1",
day = "1",
doi = "10.1038/leu.2015.185",
language = "English (US)",
volume = "30",
pages = "86--93",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas

AU - Divakar, S. K.A.

AU - Ramana Reddy, M. V.

AU - Cosenza, S. C.

AU - Baker, S. J.

AU - Perumal, D.

AU - Antonelli, A. C.

AU - Brody, J.

AU - Akula, B.

AU - Parekh, S.

AU - Premkumar Reddy, E.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - This study describes the characterization of a novel kinase inhibitor, ON123300, which inhibits CDK4/6 (cyclin-dependent kinases 4 and 6) and phosphatidylinositol 3 kinase-δ (PI3K-δ) and exhibits potent activity against mantle cell lymphomas (MCLs) both in vitro and in vivo. We examined the effects of PD0332991 and ON123300 on cell cycle progression, modulation of the retinoblastoma (Rb) and PI3K/AKT pathways, and the induction of apoptosis in MCL cell lines and patient-derived samples. When Granta 519 and Z138C cells were incubated with PD0332991 and ON123300, both compounds were equally efficient in their ability to inhibit the phosphorylation of Rb family proteins. However, only ON123300 inhibited the phosphorylation of proteins associated with the PI3K/AKT pathway. Cells treated with PD0332991 rapidly accumulated in the G0/G1 phase of cell cycle as a function of increasing concentration. Although ON123300-treated cells arrested similarly at lower concentrations, higher concentrations resulted in the induction of apoptosis, which was not observed in PD0332991-treated samples. Mouse xenograft assays also showed a strong inhibition of MCL tumor growth in ON123300-treated animals. Finally, treatment of ibrutinib-sensitive and-resistant patient-derived MCLs with ON123300 also triggered apoptosis and inhibition of the Rb and PI3K/AKT pathways, suggesting that this compound might be an effective agent in MCL, including ibrutinib-resistant forms of the disease.

AB - This study describes the characterization of a novel kinase inhibitor, ON123300, which inhibits CDK4/6 (cyclin-dependent kinases 4 and 6) and phosphatidylinositol 3 kinase-δ (PI3K-δ) and exhibits potent activity against mantle cell lymphomas (MCLs) both in vitro and in vivo. We examined the effects of PD0332991 and ON123300 on cell cycle progression, modulation of the retinoblastoma (Rb) and PI3K/AKT pathways, and the induction of apoptosis in MCL cell lines and patient-derived samples. When Granta 519 and Z138C cells were incubated with PD0332991 and ON123300, both compounds were equally efficient in their ability to inhibit the phosphorylation of Rb family proteins. However, only ON123300 inhibited the phosphorylation of proteins associated with the PI3K/AKT pathway. Cells treated with PD0332991 rapidly accumulated in the G0/G1 phase of cell cycle as a function of increasing concentration. Although ON123300-treated cells arrested similarly at lower concentrations, higher concentrations resulted in the induction of apoptosis, which was not observed in PD0332991-treated samples. Mouse xenograft assays also showed a strong inhibition of MCL tumor growth in ON123300-treated animals. Finally, treatment of ibrutinib-sensitive and-resistant patient-derived MCLs with ON123300 also triggered apoptosis and inhibition of the Rb and PI3K/AKT pathways, suggesting that this compound might be an effective agent in MCL, including ibrutinib-resistant forms of the disease.

UR - http://www.scopus.com/inward/record.url?scp=84953350470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953350470&partnerID=8YFLogxK

U2 - 10.1038/leu.2015.185

DO - 10.1038/leu.2015.185

M3 - Article

C2 - 26174628

AN - SCOPUS:84953350470

VL - 30

SP - 86

EP - 93

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -